These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25261259)

  • 1. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
    Merseburger AS; Hammerer P; Rozet F; Roumeguère T; Caffo O; da Silva FC; Alcaraz A
    World J Urol; 2015 Aug; 33(8):1079-85. PubMed ID: 25261259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
    Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup
    Ann Acad Med Singap; 2015 Oct; 44(10):397-405. PubMed ID: 26763057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment sequencing in metastatic castrate-resistant prostate cancer.
    Sartor O; Gillessen S
    Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
    Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
    Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic castration-resistant prostate cancer: time for innovation.
    Tucci M; Scagliotti GV; Vignani F
    Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
    Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
    Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
    Bahl A
    Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].
    Berlin A; Fernández MI
    Rev Med Chil; 2015 Feb; 143(2):223-36. PubMed ID: 25860365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing of agents in castration-resistant prostate cancer.
    Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
    Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer in 2014: The year chemotherapy finally gets some respect!
    Saad F
    Nat Rev Urol; 2015 Feb; 12(2):71-2. PubMed ID: 25600097
    [No Abstract]   [Full Text] [Related]  

  • 15. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment options for patients with metastatic prostate cancer.
    Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
    Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New agents in the arsenal to fight castrate-resistant prostate cancer.
    Ezzell EE; Chang KS; George BJ
    Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.
    Ferraldeschi R; Welti J; Luo J; Attard G; de Bono JS
    Oncogene; 2015 Apr; 34(14):1745-57. PubMed ID: 24837363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How to manage patients with CRPC?].
    Beuzeboc P; Massard C
    Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment strategies for advanced prostate cancer].
    Küronya Z; Bíró K; Géczi L; Németh H
    Magy Onkol; 2015 Sep; 59(3):229-40. PubMed ID: 26339912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.